Mensinger Mike's Form 4 filing
Beta Bionics, Inc. (BBNX) · filed Feb 3, 2025
- Accession no.
- 0001415889-25-002819
- Filed
- Feb 3, 2025, 8:30 PM ET
- Trade date
- Jan 31, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 5 derivative transactions. Open-market purchases total $567.0K. Open-market sales total $221. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mensinger MikeCIK 0002048500 | Officer (Chief Product Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2025 | Common Stock | CConversionAcquired | +15,107 | –F1 | – | 15,107 | Direct | |
| Jan 31, 2025 | Common Stock | XIn-the-money exerciseAcquired | +10,575 | $0.02 | +$211.5 | 25,682 | Direct | |
| Jan 31, 2025 | Common Stock | SSaleDisposed | −13 | $17.00 | −$221 | 25,669 | Direct | |
| Jan 31, 2025 | Common Stock | PPurchaseAcquired | +33,350 | $17.00 | +$566,950 | 59,019 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2025 | Common Stock | CConversionDisposed | −15,107 | –F1 | – | 0 | Direct | |
| Jan 31, 2025 | Common Stock | CConversionAcquired | +10,575 | $0.00 | $0 | 10,575 | Direct | |
| Jan 31, 2025 | Common Stock | XIn-the-money exerciseDisposed | −10,575 | $0.00 | $0 | 0 | Direct | |
| Jan 31, 2025 | Common Stock | AGrant or awardAcquired | +236,553 | $0.00 | $0 | 236,553 | Direct | |
| Jan 31, 2025 | Common Stock | AGrant or awardAcquired | +110,278 | $0.00 | $0 | 110,278 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.